ATLANTA, GA – – (Globe Newswire – June 10, 2025) – – A shareholder class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about PepGen’s business, operations, and prospects, including allegations that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was deficient for purposes of U.S. Food and Drug Administration (“FDA”) approval; and (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51’s clinical, regulatory, and commercial prospects were overstated.

If you purchased shares of PepGen between March 7, 2024 and March 3, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/pepgen/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is August 8, 2025.